Valeant Must Sell Three Rx Dermatology Drugs To Acquire Dermik and Ortho Dermatologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission requires Valeant to sell BenzaClin and 5FU to Mylan and Refissa to Spear Pharmaceuticals; Valeant also must produce a backup supply of 5FU until Mylan can manufacture the drug commercially.